Top Massachusetts Biotech Startups (225)

Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, Click delivers accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Click’s treatments are defined by a commitment to applying technical and scientific rigor and patient-centric design to the development process. This...

Synterex is a woman-owned, disability-owned business that provides clinical solutions, including publishing, clinical science, project management, medical and regulatory writing services, and IT collaboration services, from process development and optimization to document production. Our staffers are seasoned and dedicated, with extensive experience doing the work hands-on as well as building and leading teams. We are committed to applying our years of...

Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity. The company is leveraging the Rhythm Engine -- comprised of its TEMPO Registry, GO-ID genotyping study and Uncovering Rare Obesity program -- to improve the understanding, diagnosis and potentially the treatment of these disorders. For healthcare professionals, visit www.RareObesity.com for...

Driven by science and passionate about advancing patient care, DynamiCure is translating breakthrough insights on immuno-normalization into a pipeline of innovative antibody candidates with first-in-class and best-in-class potential to treat cancer, autoimmune, and other diseases. Our core values - Empathy, Dedication, Collaboration, Transparency - are at the heart of everything we do, inspired by each other and our partners to...

2020 Onsite (also known as 20/20 Onsite) is the only provider solely dedicated to point-of-need eye assessments for clinical trials, proven to meet screening timelines, improve retention rates, and fast-track trials. With over 85,000 eye exams performed, support for 45 clinical trials, and an average of 11+ years of ophthalmic expertise per clinical employee, 20/20 Onsite delivers unmatched mobile ophthalmic experience...

Senda Biosciences, Inc. is uniquely positioned to transform human health by harnessing millions of years of evolution to program targeted, potent and tunable medicines. Nature has provided the codes to program human cells – both within the cell (mRNA), and, remarkably, to the cell - using what surrounds it. The trillions of non-human cells in the human ecosystem have evolved...

Strand was started by biological engineers working together at MIT. Building on the idea of creating smart therapies that are capable of making sophisticated decisions, they sought to apply the concept of the emerging field of mRNA therapeutics. This area was untapped by traditional synthetic biology, which led them to build their own mRNA “programming language,” creating the world’s first...

Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Our proprietary Gene Traffic Control® platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug...

Atavistik Bio is a new, privately-held biopharmaceutical company focused on the discovery and development of novel therapies for metabolic diseases and cancer. Our high-throughput platform for the unbiased identification of metabolite-protein interactions will enable the discovery of first-in-class drugs inspired and empowered by nature’s own mechanisms of allosteric control. Our unique approach marries this validated platform with structure-aided drug design...

Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have...

Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in...

ZAGENO is on a mission to accelerate scientific innovation by streamlining biotech purchasing processes with its award-winning, first-of-its-kind e-commerce platform. With over 25 million product SKUs available from more than 5,000 unique product brands, ZAGENO makes online shopping for any research material convenient, efficient and reliable. The ZAGENO experience includes its Scientific Score, a best-in-class product rating system that offers...

Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s programs apply our cytoDriveTM technology in cell and gene therapy products to control expression of proteins for enhanced therapeutic efficacy, including our lead program cytoTIL15 engineered to make TILs more effective for more patients. Our aspirations are high, and we’re built...

We work at the frontier of programmable medicines. We power our bioplatform and product candidates by harnessing evolution and AI. We operate with purpose and urgency on behalf of people everywhere. We aim to generate life-changing impact for the world

Dianthus is a biotechnology company dedicated to designing and delivering the next generation of best-in-class monoclonal antibodies with improved selectivity and potency. Led by a multidisciplinary team of seasoned biotech entrepreneurs and scientists, we are pioneering selective antibodies of validated and emerging complement targets to allow people with rare and severe autoimmune diseases live healthier lives to their fullest potential.

Landmark Bio is a collective endeavor launched by leaders from academia, the life sciences industry, and world-renowned research hospitals to accelerate development and industrialization of next-generation genomic medicine. Inspired by recent advancements in cell and gene therapy, Landmark Bio was established to remove barriers in drug development, create accessible capability, expertise, and solutions, and offer a collaboration platform to advance manufacturing...

We've experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, we've developed a simple blood test to uncover actionable disease-defining transcriptional biology. Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual...

Curiox Biosystems is committed to enabling accurate biological analysis through automation. Next-generation methods and applications--including single-cell 'omics technologies, flow cytometry, immunotherapy, and cell and gene therapy--deserve a next-generation approach to preparing samples for analysis. That’s why Curiox invented Laminar Wash technology, the only sample preparation method that eliminates centrifugation and the problems it introduces. The methodology keeps cells in their...

Manifold is an AI platform purpose-built for the life sciences industry, addressing a critical challenge: despite major advances in biology, data generation, and AI, progress in drug development has slowed due to fragmented data, brittle infrastructure, and workflows not designed for secure collaboration or AI-driven analysis. The Problem We Solve: Life sciences is a $2 trillion industry where productivity directly impacts patient...

Our team develops simple, efficient procure-to-pay solutions for biotech research organizations as they develop life-saving therapies for the world's most serious health problems. Prendio is proud to play a small part in this important healing mission.